FKBP5 mRNA表达是糖皮质激素受体拮抗作用的生物标志物
本研究在健康受试者中建立血液FKBP5 mRNA定量PCR检测,并用于评估糖皮质激素受体拮抗剂对泼尼松诱导的FKBP5表达的抑制作用。口服泼尼松使FKBP5 mRNA在4小时内升至约12倍峰值、24小时内回落至基线,米非司酮或选择性GR拮抗剂CORT125134可抑制该诱导。作者认为FKBP5 mRNA表达抑制是GR拮抗作用的潜在临床生物标志物。
要点
- 健康受试者口服泼尼松后FKBP5 mRNA约4小时内升至约12倍峰值,24小时内回落至基线。
- 米非司酮或选择性GR拮抗剂CORT125134可抑制泼尼松介导的FKBP5 mRNA升高。
- 作者认为FKBP5 mRNA表达抑制是GR拮抗作用的潜在临床生物标志物。
核心结论
- 抑制FKBP5 mRNA表达是选择性GR拮抗作用的潜在临床生物标志物。
研究设计与样本
- 研究为一项I期研究,健康受试者接受单剂泼尼松联合或不联合单次口服米非司酮或GR拮抗剂CORT125134,或每日多次口服CORT125134共14天并在末次给药时合用泼尼松;于选定时间点采血,用定量PCR分析FKBP5 mRNA。
- 研究在Quotient Clinical(英国诺丁汉)开展。
主要发现
- 健康受试者口服泼尼松后FKBP5 mRNA呈时间依赖性升高,给药4小时内达约12倍于未刺激水平的峰值,随后24小时内降至基线水平。
- 口服米非司酮或选择性GR拮抗剂CORT125134可抑制泼尼松介导的GR激活,表现为FKBP5 mRNA水平降低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Endogenous Cushing's syndrome is caused by chronically elevated levels of cortisol. Mifepristone, a glucocorticoid receptor (GR) antagonist, is approved for the treatment of Cushing's syndrome. Currently there is an unmet clinical need for a direct biochemical method for monitoring the immediate effectiveness of mifepristone in patients with Cushing's syndrome. The glucocorticoid induction of FK506-binding protein 5 (FKBP5) expression is rapid and has been shown to be attenuated by GR antagonists in a range of in vitro and in vivo models. OBJECTIVE: The objective of the study was to develop a quantitative PCR assay for FKBP5 mRNA expression in blood and apply it to measure the inhibition of glucocorticoid-induced FKBP5 expression by GR antagonists in healthy human subjects. METHODS: Briefly, blood samples were acquired from a phase I study in which healthy human subjects were administered either a single dose of the GR agonist prednisone with and without coadministration of a single oral dose of mifepristone or glucocorticoid receptor antagonist (CORT125134) or multiple daily doses of CORT125134 over 14 days with coadministration of prednisone with the final dose. FKBP5 mRNA levels were analyzed by quantitative PCR in blood samples collected at selected time points. SETTING: The study was conducted at Quotient Clinical (Nottingham, United Kingdom). RESULTS: Oral administration of the glucocorticoid prednisone to healthy human subjects resulted in a time-dependent increase of FKBP5 mRNA to peak levels of approximately 12-fold compared with unstimulated levels within 4 hours of steroid administration, followed by a reduction to baseline levels within 24 hours. Furthermore, oral administration of mifepristone or the selective GR antagonist CORT125134 had the desired effect of inhibiting prednisone-mediated activation of GR as seen by a reduction of FKBP5 mRNA levels. CONCLUSIONS: The inhibition of FKBP5 mRNA expression by a selective GR antagonist is a potential clinical biomarker of GR antagonism.
引用
- Bali U, Phillips T, Hunt H, et al. FKBP5 mRNA Expression Is a Biomarker for GR Antagonism. J Clin Endocrinol Metab. 2016. PMID: 27459525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。